Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $222
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Kelsey Goodwin maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $210 to $222.
Piper Sandler analyst Kelsey Goodwin maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $210 to $222.